Suppr超能文献

澳大利亚多家医院网络中针对医院获得性多重耐药病原体的联合基因组和流行病学监测计划的初步研究。

Pilot study of a combined genomic and epidemiologic surveillance program for hospital-acquired multidrug-resistant pathogens across multiple hospital networks in Australia.

机构信息

Microbiological Diagnostic Unit (MDU) Public Health Laboratory, Department of Microbiology & Immunology at the Peter Doherty Institute for Infection & Immunity, University of Melbourne, Melbourne, Victoria, Australia.

Department of Microbiology & Immunology at the Peter Doherty Institute for Infection & Immunity, University of Melbourne, Melbourne, Victoria, Australia.

出版信息

Infect Control Hosp Epidemiol. 2021 May;42(5):573-581. doi: 10.1017/ice.2020.1253. Epub 2020 Nov 26.

Abstract

OBJECTIVES

To conduct a pilot study implementing combined genomic and epidemiologic surveillance for hospital-acquired multidrug-resistant organisms (MDROs) to predict transmission between patients and to estimate the local burden of MDRO transmission.

DESIGN

Pilot prospective multicenter surveillance study.

SETTING

The study was conducted in 8 university hospitals (2,800 beds total) in Melbourne, Australia (population 4.8 million), including 4 acute-care, 1 specialist cancer care, and 3 subacute-care hospitals.

METHODS

All clinical and screening isolates from hospital inpatients (April 24 to June 18, 2017) were collected for 6 MDROs: vanA VRE, MRSA, ESBL Escherichia coli (ESBL-Ec) and Klebsiella pneumoniae (ESBL-Kp), and carbapenem-resistant Pseudomonas aeruginosa (CRPa) and Acinetobacter baumannii (CRAb). Isolates were analyzed and reported as routine by hospital laboratories, underwent whole-genome sequencing at the central laboratory, and were analyzed using open-source bioinformatic tools. MDRO burden and transmission were assessed using combined genomic and epidemiologic data.

RESULTS

In total, 408 isolates were collected from 358 patients; 47.5% were screening isolates. ESBL-Ec was most common (52.5%), then MRSA (21.6%), vanA VRE (15.7%), and ESBL-Kp (7.6%). Most MDROs (88.3%) were isolated from patients with recent healthcare exposure.Combining genomics and epidemiology identified that at least 27.1% of MDROs were likely acquired in a hospital; most of these transmission events would not have been detected without genomics. The highest proportion of transmission occurred with vanA VRE (88.4% of patients).

CONCLUSIONS

Genomic and epidemiologic data from multiple institutions can feasibly be combined prospectively, providing substantial insights into the burden and distribution of MDROs, including in-hospital transmission. This analysis enables infection control teams to target interventions more effectively.

摘要

目的

开展一项针对医院获得性多药耐药菌(MDRO)的基因组和流行病学联合监测的试点研究,以预测患者之间的传播,并估计 MDRO 传播的本地负担。

设计

试点前瞻性多中心监测研究。

地点

该研究在澳大利亚墨尔本的 8 所大学医院(共 2800 张床位)进行,包括 4 所急性护理医院、1 所专门癌症护理医院和 3 所亚急性护理医院。

方法

从 2017 年 4 月 24 日至 6 月 18 日期间,所有住院患者的临床和筛查分离株均被采集用于检测 6 种 MDRO:vanA VRE、MRSA、ESBL 大肠埃希菌(ESBL-Ec)和肺炎克雷伯菌(ESBL-Kp),以及耐碳青霉烯类铜绿假单胞菌(CRPa)和鲍曼不动杆菌(CRAb)。分离株由医院实验室按常规进行分析和报告,在中央实验室进行全基因组测序,并使用开源生物信息学工具进行分析。使用基因组学和流行病学数据综合评估 MDRO 负担和传播情况。

结果

共从 358 名患者中采集了 408 株分离株;47.5%为筛查分离株。最常见的是 ESBL-Ec(52.5%),其次是 MRSA(21.6%)、vanA VRE(15.7%)和 ESBL-Kp(7.6%)。大多数 MDRO(88.3%)是从近期有医疗保健接触史的患者中分离出来的。基因组学和流行病学相结合确定,至少有 27.1%的 MDRO 是在医院获得的;如果没有基因组学,这些传播事件中的大多数都不会被发现。vanA VRE 的传播比例最高(88.4%的患者)。

结论

来自多个机构的基因组学和流行病学数据可以进行前瞻性结合,从而深入了解 MDRO 的负担和分布情况,包括医院内传播情况。这种分析使感染控制团队能够更有效地针对干预措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验